Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
31 October 2014Website:
http://www.biosig.comNext earnings report:
20 May 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 21 Nov 2024 00:51:31 GMTDividend
Analysts recommendations
Institutional Ownership
BSGM Latest News
Los Angeles, CA, Nov. 13, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or “Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced that it has received notice from the Nasdaq Listing Qualifications staff ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule").
Los Angeles, CA, Oct. 22, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM) (“BioSig” or the “Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced its successful appeal to the NASDAQ Panel, and as a result the Company's common stock will resume trading on the NASDAQ Capital Market Exchange at the open of trading on Wednesday, October 23, 2024. The Company was granted an extension until March 7, 2025, a 360-day grace period from the point at which the Market Value of Listed Securities (“MVLS”) requirement previously became non-compliant.
Westport, CT, June 10, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) or (“BioSig” or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced the appointment of Mr. Ferdinand Groenewald to the position of interim Chief Financial Officer. Personal Bio, Ferdinand Groenewald, age 39Ferdinand Groenewald is a certified public accountant with significant experience in finance and accounting. He currently serves as Vice President, Finance at Alaunos Therapeutics, Inc. Previously, Mr. Groenewald served as an Independent Outside Director at SYLA Technologies Co., Ltd.; an Independent Director at HeartCore Enterprises, Inc.; an Independent Director at Sushi Ginza Onodera, Inc.; an Accountant at Wrinkle, Gardner & Co. PC; a Senior Staff Accountant at Financial Consulting Strategies LLC; a Controller, VP-Finance & Accounting Officer at Sadot Group, Inc. and a Chief Financial Officer at the same company; and Chief Accounting Officer & VP-Finance at Muscle Maker Development LLC. Mr. Groenewald obtained an undergraduate degree from the University of South Africa.
Westport, CT, May 30, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 1,570,683 shares of its common stock at a purchase price of $1.91 per share and concurrent private placement unregistered warrants to purchase up to 1,570,683 shares of common stock at an exercise price of $1.78 per share. The unregistered warrants are immediately exercisable and will expire five years from the date of issuance.
BioSig's (BSGM) subscription model for PURE EP provides electrophysiologists and cardiology departments with flexibility.
BioSig Technologies (NASDAQ: BSGM ) stock is rising higher on Thursday as subsidiary BioSig AI Sciences joins Nvidia's (NASDAQ: NVDA ) Inception program. The Inception program is one that Nvidia uses to select companies with promising developments in the AI and data sciences spaces.
The foundation of BioSig's (BSGM) AI medical device platform is set to be built upon integrated healthcare datasets.
What type of business is BioSig Technologies?
BioSig Technologies, Inc., a medical technology company, focuses on deciphering the body's electrical signals starting with heart rhythms. It delivers unprecedented cardiac signal clarity, ending the reliance on mixed signals and reading between the lines. The company's product, the PURE EP Platform, provides real-time signal visualization allowing physicians to perform targeted cardiac ablation procedures with increased procedural efficiency and efficacy. The company has a research agreement with Mayo Foundation to develop an AI- and machine learning-powered software for PURE EP system. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.
What sector is BioSig Technologies in?
BioSig Technologies is in the Healthcare sector
What industry is BioSig Technologies in?
BioSig Technologies is in the Medical Devices industry
What country is BioSig Technologies from?
BioSig Technologies is headquartered in United States
When did BioSig Technologies go public?
BioSig Technologies initial public offering (IPO) was on 31 October 2014
What is BioSig Technologies website?
https://www.biosig.com
Is BioSig Technologies in the S&P 500?
No, BioSig Technologies is not included in the S&P 500 index
Is BioSig Technologies in the NASDAQ 100?
No, BioSig Technologies is not included in the NASDAQ 100 index
Is BioSig Technologies in the Dow Jones?
No, BioSig Technologies is not included in the Dow Jones index
When was BioSig Technologies the previous earnings report?
No data
When does BioSig Technologies earnings report?
The next expected earnings date for BioSig Technologies is 20 May 2025